Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Szpechcinski, J. Chorostowska-Wynimko, W. Kupis, K. Maszkowska-Kopij, J. Zaleska, E. Radzikowska, E. Puscinska, P. Sliwinski, T. Orlowski, K. Roszkowski-Sliz (Warsaw, Poland). Plasma DNA concentration and integrity measurement for NSCLC diagnostics and radical therapy effectiveness monitoring. Eur Respir J 2012; 40: Suppl. 56, 760

Member's Comments

No comment yet.

Related content which might interest you: Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer Source: Eur Respir J 2010; 36: 885-892 Year: 2010 The clinical significance of plasma DNA quantification in NSCLC Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011 Prediction of long-term effect of anti-angiogenic therapy in lung cancer patients by monitoring early changes in circulating-tumor DNA (ctDNA). Source: Virtual Congress 2020 – Biological aspects of lung cancer Year: 2020 Anti-cancer therapy and monitoring plasma concentration of carboplatin in lung cancer patients receiving hemodialysis Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Free plasmatic circulating DNA as prognostic and diagnostic lung cancer biomarker Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases Year: 2008 Circulating free DNA concentration is an independent prognostic biomarker in lung cancer Source: Eur Respir J 2015; 46: 1773-1780 Year: 2015 Dynamic monitoring of EGFR mutations in circulating tumor DNA for early detection of drug resistance in NSCLC patients on EGFR-TKI therapy Source: International Congress 2019 – Diagnostic procedures and biology of lung cancer Year: 2019 Circulating cell free RNA level and clinical response to the chemotherapy in patients with thoracic malignancy Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009 Clinicopathological significance and prognostic importance of circulating plasma DNA expression in advanced non-small cell lung cancer and its efficacy as a diagnostic tool Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012 Diagnostic work-up in stage III NSCLC including assessment of fitness for radical therapy Source: International Congress 2019 – Locally advanced non-small cell lung cancer in 2019: novel diagnostic and therapeutic strategies to tackle complex stage III disease Year: 2019 Cost-effectiveness of biomarker testing for treatment choices in advanced non-small cell lung carcinoma: impact of diagnostic strategies and their turnaround times Source: Eur Respir J, 51 (6) 1800602; 10.1183/13993003.00602-2018 Year: 2018 Cost-effectiveness of biomarker testing for treatment choices in advanced non-small cell lung carcinoma: impact of diagnostic strategies and their turnaround times Source: Eur Respir J, 51 (6) 1800844; 10.1183/13993003.00844-2018 Year: 2018 Usefulness of determination of tumour markers TPA and cyfra 21.1 in follow up study after radical therapy in patients with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001 Effective anti-tuberculosis therapy correlates with plasma small RNA Source: Eur Respir J 2015; 45: 1741-1744 Year: 2015 Influence of the limited lung function to the outcome of the surgical treatment in patients with NSCLC Source: Annual Congress 2003 - Lung function testing for preoperative evaluation in lung cancer patients Year: 2003 Dynamic monitoring of plasma DAMP proteins during various anticancer agents in advanced lung cancer patients Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020 Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients? Source: Eur Respir J 2015; 46: 1548-1550 Year: 2015 Quantification of free RNA in serum and bronchial lavage - a new tool for lung cancer detection? Source: Annual Congress 2004 - Molecular biology Year: 2004 Serum KL-6 as a biomarker for interstitial lung diseases in a clinical setting: application of a fully automated immunoassay. Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia Year: 2019